Filed Pursuant to Rule 424(b)(5)
Registration No. 333-266814
PROSPECTUS SUPPLEMENT
(To Prospectus dated August 12, 2022)
$269,428,328
Common Stock
We have entered into a sales agency financing agreement with Barclays Capital Inc. (“Barclays”) relating to the issuance, offer and sale of shares of our common stock. We refer to Barclays, when acting in this capacity, as the sales agent. In accordance with the terms of the sales agency financing agreement, we may offer and sell up to $600,000,000 of common stock from time to time through the sales agent (acting in its capacity as sales agent or as forward seller, as described below). We have offered and sold shares of common stock having an aggregate gross sales price of $330,571,672 through the date of this prospectus supplement pursuant to a previous prospectus supplement and accompanying prospectus. As a result of such prior sales, as of the date of this prospectus supplement, shares of common stock having an aggregate gross sales price of up to $269,428,328 remain available for offer and sale under the sales agency financing agreement pursuant to this prospectus supplement and the accompanying prospectus.
The sales agency financing agreement provides that, in addition to the issuance and sale of shares of common stock by us through the sales agent, we also may enter into forward sale contracts under a master forward sale agreement and one or more related supplemental confirmations between us and Barclays Bank PLC, an affiliate of Barclays. We refer to Barclays Bank PLC, when acting in this capacity, as the forward purchaser. In connection with each particular forward sale contract, the forward purchaser or its affiliate will, at our request, use commercially reasonable efforts, consistent with its normal trading and sales practices for similar transactions and applicable laws and regulations, to borrow from third parties and, through the sales agent, sell a number of shares of common stock equal to the number of shares of common stock underlying the particular forward sale contract. We refer to the sales agent, when acting as agent for the forward purchaser, as the forward seller. In no event will the aggregate number of shares of common stock sold through the sales agent, acting as an agent for the forward seller, be in excess of $269,428,328, which is the aggregate gross sales price of shares of common stock available for offer and sale under the sales agency financing agreement pursuant to this prospectus supplement and the accompanying prospectus.
The sales, if any, of shares of common stock under the sales agency financing agreement will be made in “at the market” offerings as defined in Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Global Select Market (“Nasdaq”), the existing trading market for our common stock, or sales made to or through a market maker or through an electronic communications network. In addition, shares of common stock may be offered and sold by other methods, including privately negotiated transactions, as we and the sales agent (and related forward seller and forward purchaser) agree to in writing. We also may sell shares of common stock to the sales agent, acting as principal for its own account, at a price to be agreed upon at the time of sale. If we sell shares of common stock to the sales agent, acting as principal, we will enter into a separate terms agreement with the agent, and we will describe the terms agreement in a separate prospectus supplement or pricing supplement.
If we enter into forward sale contracts, we will not initially receive any proceeds from the sale of borrowed shares of common stock by the forward seller. We expect to fully physically settle each particular forward sale contract with the forward purchaser on one or more dates specified by us on or prior to the maturity date of that particular forward sale contract, in which case we will expect to receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward sale contract multiplied by the relevant forward sale price. However, we may also elect to cash settle or net share settle a particular forward sale contract, in which case we will not receive any proceeds from the sale of the borrowed shares of common stock by the forward seller and, depending on movements in the price of our common stock during the term of the relevant forward contract, we may owe or be owed cash upon settlement (in the case of cash settlement), or we may be required to deliver or be entitled to receive shares of common stock upon settlement (in the case of net share settlement).
The sales agent will offer our common stock at market prices prevailing at the time of sale and will provide written confirmation to us of such sales no later than the opening of the trading on Nasdaq on the following trading day. Each confirmation will include the number of shares of common stock sold on the preceding day, the net proceeds to us and the compensation payable by us to the sales agent in connection with such sales. We will pay the sales agent a commission at a mutually agreed rate that will not exceed, but may be lower than, 2.0% of the sales price of all of the shares of common stock issued by us and sold through it as our sales agent under the sales agency financing agreement. In connection with each forward sale contract, we will pay the forward seller, in the form of a reduced initial forward sale price under the related forward sale contract with the forward purchaser, commissions at a mutually agreed rate that will not exceed, but may be lower than, 2.0% of the sales prices of all borrowed shares of common stock sold during the applicable forward hedge selling period by it as forward seller. If the sales agent and/or forward seller, as applicable, engages in special selling efforts, as that term is used in Regulation M under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the sales agent and/or forward seller, as applicable, will receive from us a commission to be agreed upon at the time of sale.
Our common stock is listed on Nasdaq under the symbol “GLPI.” On August 11, 2022, the last reported sale price of our common stock on Nasdaq was $51.49 per share. You are urged to obtain current market quotations of our common stock.
To ensure that we maintain our qualification as a real estate investment trust (“REIT”), our articles of incorporation impose certain restrictions on ownership of our common stock. See “Description of Capital Stock of GLPI—Restrictions on Ownership and Transfer” in the accompanying prospectus.
Investing in our common stock involves risks. You should read carefully and consider the “Risk Factors” sections beginning on page S-5 of this prospectus supplement and in our most recent Annual Report on Form 10-K, as updated by our subsequent filings under the Exchange Act, to the extent incorporated by reference in this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
No gaming or regulatory agency has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Barclays
Prospectus Supplement dated August 12, 2022